ABPI have been denied the opportunity to legally challenge incorporation of the £20 million budget impact test being incorporated into NICE assessments.
Read the full article here
We examine the effects on patient access, specifically regarding pathways, high value steps, multi-i...
Our analysts explore NICE's integration of tech appraisals into treatment guidelines for to enable o...
Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.
Remap Consulting have significant experience working with pharmaceutical and biotech companies in helping them navigate global market access.